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BACKGROUND: Wet or productive cough is common in children with chronic cough. We
formulated recommendations based on systematic reviews related to the management of
chronic wet cough in children (aged # 14 years) based on two key questions: (1) how
effective are antibiotics in improving the resolution of cough? If so, what antibiotic should be
used and for how long? and (2) when should children be referred for further investigations?
METHODS: We used the CHEST expert cough panel’s protocol for systematic reviews and the
American College of Chest Physicians (CHEST) methodologic guidelines and GRADE
framework (the Grading of Recommendations Assessment, Development and Evaluation).
Data from the systematic reviews in conjunction with patients’ values and preferences and
the clinical context were used to form recommendations. Delphi methodology was used to
obtain consensus for the recommendations/suggestions made.
RESULTS: Combining data from the systematic reviews, we found high-quality evidence in
children aged# 14 years with chronic (> 4 weeks’ duration) wet/productive cough that using
appropriate antibiotics improves cough resolution, and further investigations (eg, ﬂexible
bronchoscopy, chest CT scans, immunity tests) should be undertaken when speciﬁc cough
pointers (eg, digital clubbing) are present. When the wet cough does not improve following
4 weeks of antibiotic treatment, there is moderate-quality evidence that further investigations
should be considered to look for an underlying disease. New recommendations include the
recognition of the clinical diagnostic entity of protracted bacterial bronchitis.
CONCLUSIONS: Compared with the 2006 Cough Guidelines, there is now high-quality evi-
dence for some, but not all, aspects of the management of chronic wet cough in specialist
settings. However, further studies (particularly in primary health) are required.
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Summary of Recommendations/Suggestions
1. For children aged £ 14 years with chronic
(> 4 weeks’ duration) wet or productive cough
unrelated to an underlying disease and without any
speciﬁc cough pointers (eg, coughing with feeding,
digital clubbing), we recommend that children receive
2 weeks of antibiotics targeted to common respiratory
bacteria (Streptococcus pneumoniae, Haemophilus
inﬂuenzae, Moraxella catarrhalis) and local antibiotic
sensitivities (Grade 1A).
2. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and without any speciﬁc cough pointers (eg, coughing
with feeding, digital clubbing) and whose cough
resolves within 2 weeks of treatment with antibiotics
targeted to local antibiotic sensitivities, we
recommend that the diagnosis of protracted bacterial
bronchitis (PBB) be made (Grade 1C).
3. For children aged £ 14 years with PBB with lower
airway (bronchoalveolar lavage or sputum)
conﬁrmation of clinically important density of
respiratory bacteria (‡ 104 cfu/ml), we recommend
that the term ‘microbiologically-based-PBB’ (or PBB-
micro) be used to differentiate it from clinically-
based-PBB (PBB without lower airway bacteria
conﬁrmation) (Grade 1C).
4. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and without any speciﬁc cough pointers (eg, coughing
with feeding, digital clubbing) when the wet cough
persists after 2 weeks of appropriate antibiotics, we
recommend treatment with an additional 2 weeks of
the appropriate antibiotic(s) (Grade 1C).
5. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and without any speciﬁc cough pointers (eg, coughing
with feeding, digital clubbing), when the wet cough
persists after 4 weeks of appropriate antibiotics, we
suggest that further investigations (eg, ﬂexible
bronchoscopy with quantitative cultures and
sensitivities with or without chest computed
tomography) be undertaken (Grade 2B).
6. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and with speciﬁc cough pointers (eg, coughing with
feeding, digital clubbing), we recommend that further
investigations (eg, ﬂexible bronchoscopy and/or chest
computed tomography, assessment for aspiration
and/or evaluation of immunologic competency)
be undertaken to assess for an underlying disease
(Grade 1B).
7. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and without any speciﬁc cough pointers (eg, coughing
with feeding, digital clubbing), we suggest that
randomized controlled trials on the efﬁcacy of
different durations of antibiotics be undertaken in
various clinical settings (particularly in primary care)
to determine its inﬂuence on the number to treat and
recurrence. When doing so, we suggest that validated
cough outcomes and a-priori deﬁnitions be used
(Ungraded, Consensus Based Statement).
Chronic wet cough is common among children whose
parents seek medical consultations from specialty
centers.1 Young children do not usually expectorate.
Thus the term wet cough is used instead, and this is
deﬁned by its loose, self-propagating sound, was
substituted for productive cough in this age group.2
When children can expectorate, the term productive
cough is preferred.3 Decades ago, astute clinicians
recognized that early diagnosis and management of
chronic productive cough were likely important for
future lung health.4,5 Additional reasons why the
recognition and treatment of chronic wet/productive
cough in children are important were highlighted
previously.3
The 2006American College of Chest Physicians (CHEST)
guidelines on chronic cough in children6 advocated that
when a wet cough was present and there were no other
symptoms and signs (eg, dysphagia or digital clubbing),
antibiotics should be prescribed. However, this
recommendation was made with the use of limited
evidence. For the present update as required by the
CHEST Guideline Committee, we undertook systematic
reviews addressing key questions (KQs) concerning the
management of children with chronic wet or productive
cough unrelated to established chronic lung disease
(ie, when children ﬁrst present to clinicians with a
previously undiagnosed condition).3 The present article is
a summary of the evidence behind the recommendations
formulated on ﬁndings of the systemic reviews that
examined two related KQs in children with chronic
(> 4 weeks) wet or productive cough not related to
bronchiectasis. KQ1 was as follows: How effective are
antibiotics in improving the resolution of cough? If so,
what antibiotic should be used and for how long?KQ2was
as follows: When should children be referred for further
journal.publications.chestnet.org 885
investigations? The present article should be read with the
accompanying systematic review.3
In line with the CHEST cough guidelines, it was
determined a priori that the age cutoff for pediatric and
adult components was to be 14 years. Although the
recommendations address children aged # 14 years,
premature infants and neonates are excluded from these
recommendations. In premature infants and neonates,
respiratory illnesses are much more likely to manifest as
tachypnea, dyspnea, and/or hypoxemia and rarely by
chronic cough.
Materials and Methods
We used a standard method as previously used by panel members7:
“(The methodology used by the CHEST Guideline Oversight
Committee to select the Expert Cough Panel Chair and the
international panel of experts, perform the synthesis of the evidence
and develop the recommendations and suggestions has been
published.8,9 Key questions and parameters of eligibility were
developed for this topic. Existing guidelines, systematic reviews, and
primary studies were assessed for relevance and quality, and were
used to support the evidence-based graded recommendations or
suggestions. A highly structured consensus-based Delphi approach
was employed to provide expert advice on all guidance statements.
The total number of eligible voters for each guideline statement
varied based on the number of managed individuals recused from
voting on any particular statements because of their potential
conﬂicts of interest. Transparency of process was documented.
Further details of the methods have been published elsewhere.8,9)” In
line with the CHEST guideline methodology,8,9 a comprehensive,
systematic review of the literature was undertaken to provide the
evidence base for recommendations outlined here.
Guideline Framework
Aspreviously described,7 “theACCPhas adopted theGRADE framework
(the Grading of Recommendations Assessment, Development and
Evaluation). This framework separates the process of rating the quality
of evidence from that of determining the strength of recommendation.
The quality of evidence is based on the ﬁve domains of risk of bias,
inconsistency, indirectness, reporting bias, and imprecision. The quality
of evidence (ie, the conﬁdence in estimates) is rated as high (A),
moderate (B), low, or very low (C). The strength of recommendation is
determined based on the quality of evidence, balance of beneﬁts and
harms, patients’ values and preferences and availability of resources.”
Recommendations can be strong vs weak or Grade 1 vs 2 or ungraded.
State of the Available Evidence
Searches for the systematic reviews were performed externally by
librarians (Nancy Harger, MLS, and Judy Nordberg, MLS) from the
University of Massachusetts Medical School, Worcester,
Massachusetts. These searches were conducted between July 19 and
July 27, 2015, using an a priori established protocol for each KQ.3
The evidence for the KQs was summarized in a previous publication.3
The systematic review3 identiﬁed high-quality evidence to support
some recommendations but not all. Where there was insufﬁcient
evidence for diagnosis and management recommendations, the panel
heavily considered patient values, preferences, ease and cost of tests,
and availability of potential therapies. The panel also made several
suggestions for future research.
Results
The ﬁrst six recommendations and/or suggestions were
derived from ﬁndings from our systematic reviews that
addressed the aforementioned KQs.3 Diagrams
according to the Preferred Reporting Items for
Systematic Reviews and Meta-analyses statement and
included studies were presented in the prior publication.
Summary of Evidence and Interpretation
The efﬁcacy of antibiotic treatment for resolving chronic
wet cough in children was evident from three
randomized controlled trials (RCTs) in which the forest
plot from the combined RCT data showed a clear beneﬁt
(number needed to treat for beneﬁt by end of study was
3 [95% CI, 2.0-4.3]).3 Consistent with RCT data, all
other studies included in the systematic review reported
beneﬁt irrespective of the study design (eg, prospective
and retrospective studies).
However, our systematic review3 found lower level
evidence with regard to the type and duration of
antibiotics required. The duration of treatment ranged
from 1 to 8 weeks; prospective studies used a shorter
duration (7 days10,11 to 2 weeks12-17), whereas the
retrospective studies reported longer durations
(4-6 weeks18 and 6-8 weeks19). The summary of
evidence indicates that, in general, a 2-week course is
sufﬁcient but up to 4 weeks may be required in a
minority of children.3,20 The British Thoracic Society
cough guidelines21 suggest the use of 4 to 6 weeks of
antibiotics in children suspected of having protracted
bacterial bronchitis (PBB). However, our systematic
review did not identify any prospective study-derived
evidence for this statement. Although a full 4 weeks or
longer course may be needed in a minority of patients, a
shorter initial course is advocated in the current era of
judicious antimicrobial stewardship. Furthermore, one
study showed that children with chronic wet cough that
does not resolve after 4 weeks of appropriate oral
antibiotics have an increased likelihood (adjusted OR, 5.9
[95% CI, 1.2-28.5]) of CT scan-diagnosed bronchiectasis.22
Prospective and retrospective studies have found
clinically important levels of respiratory bacteria density
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($ 104 CFUs/mL) in the BAL of children with chronic
wet cough.3 The common lower airway bacteria
pathogens reported in prospective studies of children
with chronic wet cough were Haemophilus inﬂuenzae
(nontypeable when typing was done), Moraxella
catarrhalis, and Streptococcus pneumoniae.20 Other
retrospective studies also reported Staphylococcus aureus
in some (11 of 50) children with PBB,23 but quantitative
bacteriologic testing was not performed, making
interpretation difﬁcult. Amoxicillin-clavulanate was the
most commonly used single antibiotic (the primary
antibiotic in seven studies11,13,15,16,18,19,24) followed by
clarithromycin in three studies,12,14,17 erythromycin in
one study,10 and cefaclor in one study.25 The
retrospective studies used a variety of antibiotic
types.18,19,24,25
PBB was ﬁrst described in 2006.15 The criteria in the
original description of PBB were as follows: (1)
presence of chronic wet cough; (2) response (cough
resolution) to antibiotics (amoxicillin-clavulanate)
within 2 weeks of use; and (3) lower airway infection
deﬁned as the presence of respiratory pathogens at a
density $ 104 CFUs/mL BAL,15 in the absence of
evidence of infection with Bordetella pertussis,
Mycoplasma pneumoniae, or chlamydia infection
(according to polymerase chain reaction and/or
serologic testing). In a double-blind, placebo-controlled
RCT16 in which a ﬂexible bronchoscopy (FB) was
performed pretreatment (amoxicillin-clavulanate or
placebo) in a subgroup of children with chronic wet
cough, their BAL data were consistent with PBB.
However, it was not feasible or warranted that all
children with chronic wet cough undergo a FB. Thus, it
has been advocated that the third criterion be replaced
by absence of other causes of wet or productive
cough.26 Our systematic review found mechanistic or
pathobiologic studies that provide ﬁrm evidence of PBB
as a diagnostic clinical entity. We also identiﬁed several
studies that used cough management pathways in
which a key step was the use of antibiotic treatment in
children with chronic wet cough who did not have
other symptoms or signs.3 FB was not performed in
these studies when the cough resolved with antibiotic
treatment, supporting the concept of the diagnosis of
PBB without lower airway microbiology conﬁrmation
(ie, clinically deﬁned PBB).
1. For children aged £ 14 years with chronic (>
4 weeks’ duration) wet or productive cough unrelated
to an underlying disease and without any speciﬁc
cough pointers (eg, coughing with feeding, digital
clubbing), we recommend that children receive
2 weeks of antibiotics targeted to common respiratory
bacteria (Streptococcus pneumoniae, Haemophilus
inﬂuenzae, Moraxella catarrhalis) and local antibiotic
sensitivities (Grade 1A).
2. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and without any speciﬁc cough pointers (eg, coughing
with feeding, digital clubbing) and whose cough
resolves within 2 weeks of treatment with antibiotics
targeted to local antibiotic sensitivities, we
recommend that the diagnosis of protracted bacterial
bronchitis (PBB) be made (Grade 1C).
3. For children aged £ 14 years with PBB with lower
airway (bronchoalveolar lavage or sputum)
conﬁrmation of clinically important density of
respiratory bacteria (‡ 104 cfu/ml), we recommend
that the term ‘microbiologically-based-PBB’ (or PBB-
micro) be used to differentiate it from clinically-
based-PBB (PBB without lower airway bacteria
conﬁrmation) (Grade 1C).
4. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and without any speciﬁc cough pointers (eg,
coughing with feeding, digital clubbing) when the
wet cough persists after 2 weeks of appropriate
antibiotics, we recommend treatment with an
additional 2 weeks of the appropriate antibiotic(s)
(Grade 1C).
Summary of Evidence and Interpretation
Data in our systematic review on chronic wet cough22
were in agreement with those on the use of cough
management pathways27 with regard to undertaking
investigations when cough pointers (eg, coughing with
feeding, digital clubbing) (Table 1) are present and
when the wet cough does not resolve within a speciﬁc
time frame following the use of antibiotics. The type
of investigations initiated depended on the child’s
clinical features.3 However, the time frame used for
“nonresolution” following a course of antibiotics differed
among studies, although most studies used a cutoff of
4 weeks.12-15,28 Our systematic review3 also identiﬁed
two studies19,22 that described an increased risk of
the presence of underlying lung disease such as bron-
chiectasis when the cough did not respond to 2 to
4 weeks of antibiotic treatment. One additional study29
determined that longer cough duration was associated
with worse radiologic features (higher Bhalla30 score)
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and more structural airway abnormality (type of airway
obstruction31). The Bhalla score is a CT scan-derived
score in which a higher score indicates worse
bronchiectasis.
Our systematic review3 found that in the majority of
studies which described the investigation of chronic wet
cough, FB with BAL and/or chest CT scans or
assessment of immunity were the tests most commonly
performed. FB abnormalities described included tracheal
and bronchial malacia, visualization of purulent
secretions, and/or BAL data. When BAL data were
reported and, although they were interpreted by the
study authors as being consistent with infection,
quantitative bacteriologic testing was only performed in
some studies.3 The types of investigations were targeted
to the population and sampling frame. For example, in
settings with high TB exposure, appropriate tests for
Mycobacterium tuberculosis infection were required.3,28
5. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and without any speciﬁc cough pointers (eg, coughing
with feeding, digital clubbing), when the wet cough
persists after 4 weeks of appropriate antibiotics, we
suggest that further investigations (eg, ﬂexible
bronchoscopy with quantitative cultures and
sensitivities with or without chest computed
tomography) be undertaken (Grade 2B).
6. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and with speciﬁc cough pointers (eg, coughing with
feeding, digital clubbing), we recommend that further
investigations (eg, ﬂexible bronchoscopy and/or chest
computed tomography, assessment for aspiration
and/or evaluation of immunologic competency)
be undertaken to assess for an underlying disease
(Grade 1B).
Summary of Evidence and Interpretation
In addition to the lack of available information outlined
earlier, our systematic review3 was limited by the small
number of studies. In addition, all but one study were
conducted in major hospitals. Large multicenter studies
particularly in primary care will be required to build the
evidence base to inform management outside of major
hospitals or tertiary referral centers. When cough is used
as a study outcome, the use of validated outcome
measures would improve the quality of studies. The lack
of the use of validated cough outcomes and a priori
deﬁnitions are major limitations of many chronic cough
studies in children.27
7. For children aged £ 14 years with chronic wet or
productive cough unrelated to an underlying disease
and without any speciﬁc cough pointers (eg, coughing
with feeding, digital clubbing), we suggest that
randomized controlled trials on the efﬁcacy of
different durations of antibiotics be undertaken in
various clinical settings (particularly in primary care)
to determine its inﬂuence on the number to treat and
recurrence. When doing so, we suggest that validated
cough outcomes and a-priori deﬁnitions be used
(Ungraded, Consensus Based Statement).
Areas for Further Research
To advance and improve the management of chronic
wet or productive cough in children, suggested areas of
research include:
TABLE 1 ] Extended List of Cough Pointers (Modiﬁed
From Previous Articles6,26,33)
Systemic Pulmonary
 Cardiac abnormalities  Chest pain
 Digital clubbing  Daily moist or produc-
tive cough
 Failure to thrive  Hemoptysis
 Medications or drugs
associated with chronic
cough (angiotensin-
converting enzyme in-
hibitors, illicit drug use)
 Abnormal cough char-
acteristics (brassy,
plastic bronchitis,
paroxysmal with/
without posttussive
vomiting, staccato,
cough from birth)
 Neurodevelopmental
abnormality
 Recurrent pneumonia
 Fever  Hypoxia/cyanosis
 Immunodeﬁciency
(primary or secondary)
 History of previous lung
disease or predisposing
causes (eg, neonatal
lung disease, foreign
body aspiration)
 Feeding difﬁculties  Exertional dyspnea
 History of contacts (eg,
TB)
 Dyspnea at rest or
tachypnea
 Chest wall deformity
 Auscultatory ﬁndings
(eg, stridor, wheeze,
crackles)
 Chest radiograph
abnormalities
 Pulmonary function test
abnormalities
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1. Determining the outcomes of chronic wet cough
following an acute infection in various settings
(community and hospital) through the performance
of multicenter cohort studies.
2. Multicenter, parallel-group RCTs addressing the efﬁ-
cacy of antibiotics for the treatment of chronic wet
cough in primary care, using validated cough
outcome measures32 and a priori deﬁnitions of cough
resolution. Ideally, an objective cough outcome
(eg, cough counts) should also be included as an
outcome.
3. Determining the optimal length of antibiotics in
different circumstances (eg, relating to prevention of
recurrence, duration of chronic cough, type of bac-
teria, age of children).
4. Studies to address the most appropriate time point
when the child should be referred for further in-
vestigations when speciﬁc cough pointers (Table 1)
are absent and the wet cough persists after antibiotic
treatment.
5. Intervention studies to prevent recurrence of PBB,
especially for those having very frequent recurrences.
Conclusions
This update of the 2006 CHEST Cough Guidelines6
relating to chronic wet cough in children has resulted
in new recommendations formulated from systematic
reviews addressing two key clinical questions. The clinical
diagnostic entity of PBB, not mentioned in the 2006
guidelines, is now recognized. These recommendations
were endorsed by the CHEST Expert Cough Panel.
There is high-quality evidence relating to most of the
recommendations but many questions remain,
particularly in primary care, where the data are scarce.
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